Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,421 to 3,440 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| aQIV vs Comparator QIV: serious adverse events | 31 of 1,027 31 of 1,016 | -0.0 points -1.6 to 1.5 | 2,043 | NCT05044195 A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age |
| Vaccine vs Placebo: Participant Dropout After Unblinding | 241 of 1,036 309 of 999 | -7.7 points -11.5 to -3.8 | 2,035 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
| Zoledronic Acid 4 mg Q4W vs Denosumab 120 mg Q4W: serious adverse events | 471 of 1,013 453 of 1,020 | 2.1 points -2.2 to 6.4 | 2,033 | NCT00321464 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. |
| PIIA: SAPIEN XT vs Control: SAVR: All-cause Death or Disabling Stroke to Two Years | 192 of 1,011 202 of 1,021 | -0.8 points -4.2 to 2.6 | 2,032 | NCT01314313 PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk |
| PIIA: SAPIEN XT - 2 Year vs Control: SAVR - 2 Year: deaths from any cause | 166 of 1,011 170 of 1,021 | -0.2 points -3.5 to 3.0 | 2,032 | NCT01314313 PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk |
| Lasmiditan 100mg vs Lasmiditan 200mg: Number of Participants With at Least 1 Treatment Emergent Adverse Event | 447 of 991 545 of 1,039 | -7.3 points -11.7 to -3.0 | 2,030 | NCT02565186 An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine |
| Lasmiditan 100mg vs Lasmiditan 200mg: serious adverse events | 29 of 991 36 of 1,039 | -0.5 points -2.1 to 1.0 | 2,030 | NCT02565186 An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine |
| OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI Period | 48 of 1,024 58 of 1,002 | -1.1 points -3.1 to 0.9 | 2,026 | NCT00790907 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) |
| OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Major Bleeding During the Peri-PCI Period | 14 of 1,024 12 of 1,002 | 0.2 points -0.9 to 1.2 | 2,026 | NCT00790907 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) |
| OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Major Vascular Access Site Complications During the Peri-PCI Period | 33 of 1,024 43 of 1,002 | -1.1 points -2.8 to 0.6 | 2,026 | NCT00790907 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) |
| OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Minor Bleeding During the Peri-PCI Period | 7 of 1,024 17 of 1,002 | -1.0 points -2.1 to -0.1 | 2,026 | NCT00790907 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) |
| OL Fondaparinux Background + Low Dose UFH During PCI vs OL Fondaparinux Background + Standard Dose UFH During PCI: Number of Participants With Composite of Major Bleeding During the Peri-PCI Period, With Death, MI, or TVR at Day 30 | 59 of 1,024 39 of 1,002 | 1.9 points -0.0 to 3.8 | 2,026 | NCT00790907 Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) |
| EVR+rCNI vs MPA+sCNI: Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation. | 276 of 1,014 152 of 1,012 | 12.2 points 8.7 to 15.7 | 2,026 | NCT01950819 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
| EVR+rCNI vs MPA+sCNI: Incidence of Major Cardiovascular Events. | 66 of 1,014 86 of 1,012 | -2.0 points -4.3 to 0.3 | 2,026 | NCT01950819 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: deaths from any cause | 20 of 1,014 29 of 1,012 | -0.9 points -2.3 to 0.5 | 2,026 | NCT01950819 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
| EVR+rCNI vs MPA+sCNI: Incidence of Malignancies. | 41 of 1,014 39 of 1,012 | 0.2 points -1.5 to 1.9 | 2,026 | NCT01950819 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: serious adverse events | 593 of 1,014 613 of 1,012 | -2.1 points -6.4 to 2.2 | 2,026 | NCT01950819 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
| Intervention vs Control: deaths from any cause | 15 of 1,029 19 of 997 | -0.4 points -1.6 to 0.7 | 2,026 | NCT03679247 Electronic Tools to Increase Recognition and Improve Primary Care Management for Hypertension in Chronic Kidney Disease |
| Group 1: cHL vs Group 2: RRHL: deaths from any cause | 243 of 1,598 136 of 426 | -16.7 points -21.6 to -12.1 | 2,024 | NCT03327571 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes |
| Group 1: cHL vs Group 2: RRHL: serious adverse events | 303 of 1,598 103 of 426 | -5.2 points -9.9 to -0.9 | 2,024 | NCT03327571 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes |
Code
curl "https://conductscience.org/api/comparisons/v1?page=172"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=172
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05044195-sae",
"title": "aQIV vs Comparator QIV: serious adverse events",
"summary": "31 of 1027 against 31 of 1016; risk difference -0.0 points, 95% interval -1.6 to 1.5; NCT05044195, A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age",
"record": "/library/comparisons/NCT05044195-sae",
"nct_id": "NCT05044195",
"kind": "serious-adverse-events",
"participants": 2043,
"risk_difference": {
"value": -0.0003268061550728771,
"lower": -0.015613059400811593,
"upper": 0.014908878631297993
},
"group_1": "31 of 1,027",
"group_2": "31 of 1,016",
"difference": "-0.0 points",
"interval": "-1.6 to 1.5",
"trial_title": "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age"
},
{
"id": "NCT00865566-aa501b8e",
"title": "Vaccine vs Placebo: Participant Dropout After Unblinding",
"summary": "241 of 1036 against 309 of 999; risk difference -7.7 points, 95% interval -11.5 to -3.8; NCT00865566, Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",
"record": "/library/comparisons/NCT00865566-aa501b8e",
"nct_id": "NCT00865566",
"kind": "outcome",
"participants": 2035,
"risk_difference": {
"value": -0.0766838266838267,
"lower": -0.11504886213486186,
"upper": -0.03808587053316391
},
"group_1": "241 of 1,036",
"group_2": "309 of 999",
"difference": "-7.7 points",
"interval": "-11.5 to -3.8",
"trial_title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=173",
"request_id": "XgqJnzGAxtgoqLS8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant